In the BioHarmony Drug Report Database

"Preview" Icon

Ramucirumab

Cyramza (ramucirumab) is an antibody pharmaceutical. Ramucirumab was first approved as Cyramza on 2014-04-21. It is used to treat colorectal neoplasms, non-small-cell lung carcinoma, and stomach neoplasms in the USA. It has been approved in Europe to treat stomach neoplasms. The pharmaceutical is active against vascular endothelial growth factor receptor 2.

 

Trade Name

 

Cyramza
 

Common Name

 

ramucirumab
 

ChEMBL ID

 

CHEMBL1743062
 

Indication

 

colorectal neoplasms, non-small-cell lung carcinoma, stomach neoplasms
 

Drug Class

 

Monoclonal antibodies

Image (chem structure or protein)

Ramucirumab structure rendering